{"organizations": [], "uuid": "a6089e7f51df9ff631660129d4f404b733c3c7dd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/refile-table-sawai-pharmaceutical-9-mth/refile-table-sawai-pharmaceutical-9-mth-group-results-idUSL4N1Q32LT", "country": "US", "domain_rank": 408, "title": "REFILE-TABLE-Sawai Pharmaceutical- 9-MTH group results", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.91, "site_type": "news", "published": "2018-02-13T14:22:00.000+02:00", "replies_count": 0, "uuid": "a6089e7f51df9ff631660129d4f404b733c3c7dd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/refile-table-sawai-pharmaceutical-9-mth/refile-table-sawai-pharmaceutical-9-mth-group-results-idUSL4N1Q32LT", "ord_in_thread": 0, "title": "REFILE-TABLE-Sawai Pharmaceutical- 9-MTH group results", "locations": [], "entities": {"persons": [{"name": "sawai pharmaceutic", "sentiment": "negative"}, {"name": "ann div", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "recurring", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "al co ltd", "sentiment": "none"}, {"name": "sawai pharmaceutical co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds company forecast. Accounting policy for forecast is IFRS) Feb 13 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Dec 31, 2017 Dec 31, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 116.54 101.38 168.80 (+15.0 pct) (+9.7 pct) Operating 19.10 17.90 23.70 (+6.7 pct) (-7.4 pct) Recurring 19.67 17.87 23.30 (+10.1 pct) (-6.5 pct) Net 14.04 13.69 12.80 (+2.6 pct) (-2.2 pct) EPS 377.01 yen 371.35 yen 343.59 yen EPS Diluted 376.76 yen 371.13 yen Ann Div 130.00 yen 130.00 yen -Q2 div 65.00 yen 65.00 yen -Q4 div 65.00 yen 65.00 yen NOTE - Sawai Pharmaceutical Co Ltd. To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T14:22:00.000+02:00", "crawled": "2018-02-14T12:21:38.004+02:00", "highlightTitle": ""}